Exclusive: New Houston accelerator reveals its inaugural cohort and announces strategic partner

Smart Cities

The Ion Smart Cities Accelerator — named for its to-be home, The Ion — announced the 10 companies selected for the first cohort. Courtesy of Rice University

The Ion Smart Cities Accelerator launched earlier this year with a goal of engaging startups from around the world to solve some of Houston's most prevalent challenges. Backed by Intel and Microsoft and partnered with the city of Houston and Station Houston, the program has developed a curriculum and selected its first cohort.

Ten startups from around the world — half of which from right here in Houston — were selected to be a part of the program. And narrowing down to 10 was tough for the program's judges, says Christine Galib, director of the Ion Smart Cities Accelerator.

"Selecting the participants for our first cohort was difficult, due to this amazing pool of talent — that's always the problem you want to have," she tells InnovationMap.

The program will be a 10-month process, beginning Wednesday, September 4. The accelerator's Demo Day is scheduled for December 4, and then the participants will complete a pilot program with the city from January to June, Galib says.

Based on the issues the cohort aims to solve — resilience and mobility — the program and the city of Houston decided on Near Northside as a focus for the companies.

"We focused on aligning to the needs of the city of Houston and our spotlight community, Near Northside," Galib says. "We really considered the focus areas that we have identified that were needs or challenges in the area, like aging infrastructure or health and safety."

The entrepreneurs will attend local meetings, connect with the community, and zero in on the neighborhood for solutions. This provides a more accessible avenue of integration for each of the companies' technologies and allows for the entrepreneurs to receive feedback in real time from the community.

"One of my biggest things with the accelerator is technology will be for the people, and not the other way around. We're really hoping that we can build relationships with community members in Near Northside such that they'll be able to have access to our startups and their technology in a very integrated way."

Along with this new neighborhood focus, the program also announced a partnership with the University of Houston.

"We're collaborating with the UH Technology Bridge such that professors, researchers, and startups associated with UH can have a pipeline from the world of academia and research to industry and urban planning," says Galib.

Here are 10 selected startups for the inaugural cohort.

Aatonomy

Houston-based Aatonomy has developed a device that allows for Houston drivers to instal self-driving technology in their own vehicles.

"They're basically Tesla's autopilot — but for cars we already own," Galib says.

The technology makes for safer, smarter driving around town.

AeoShape

Another homegrown company, AeoShape is in the business of compiling data and making it easier to use — from facial analysis to location-based services, the company is taking data and organizing it to more easily use it for finding solutions or strategies.

"Imagine having all the big data served up anywhere at any time in a comprehensive, visual way," Galib says.

BlocPower

Based in New York, BlocPower is connecting the dots in the consumer energy world. The startup links up with government entities, utilities contractors and more to engage IoT, machine learning, and structured finance technology to better provide clean energy in American cities.

"This is pairing the different segments in the building and infrastructure world in a way that makes sense so that they can build in an integrated way," Galib says.

GoKid

Another New York company, GoKid has a solution for carpooling. In a world so conveniently filled with ridesharing technology, busy parents still struggle to find safe rides home for their kids. The free app allows for parents to connect with one another in a way never before been optimized for school pick-up and drop-off.

"We see GoKid really working with our schools here to make ridesharing safer," Galib says. "We really like them because they were a solution for the ridesharing challenge — a lot of parents who might need carpooling services don't necessarily trust an Uber driving that they don't know."

Kriterion

Artificial intelligence company Kriterion is based in South Africa, but will soon call Houston home. The company takes AI a step further in its industry and infrastructure approach.

"We see their platform shaping three areas of Houston: waste management, power system management, and pothole detection and maintenance management," says Galib.

Sensytec

 Sensytec comes out of the University of Houston and uses is technology to monitor, analyze, and quantify cement and concrete conditions.

"We thought this was pretty cool to have in our cohort because Houston is quite the concrete jungle," says Galib.

The company was also recently named a top startup in MassChallenge Texas' inaugural Houston cohort.

SlideX

Houston-based SlideX has solutions for everyone's daily struggle: Parking. The company's technology has applications for finding parking in the city — including a 3D map to help direct you — and even for paying for parking.

"They call themselves 'the next generation of intelligent parking,'" Galib says.

Umanity

San Francisco-based Umanity has created a philanthropic supply chain tool. The technology can match and map local nonprofit needs to volunteers and donations, plus provide real-time analytics.

"This is kind of the epitome of doing good and adds a very strong social enterprise and community base component to our startups," says Galib.

Wyzerr

Kentucky startup Wyzerr specializes in easy-to-use surveys.

"We think Wyzerr can provide a good feedback platform where the city of Houston, businesses, and nonprofits can easily engage with people all over the city to find out how satisfied they are with the businesses and services the city provides," Galib says.

The company's technology can be crucial for tracking KPIs and progress.

"When you're creating a Smart City, there are obviously objectives you set for what you consider to be a Smart City, but also there are ways to measure how well you're meeting those objectives," she adds.

Reality IMT

Houston-based Reality IMT is engaging the latest technology tools to digitize infrastructure.

"This really speaks to understanding our infrastructure and ways to make it safer and more efficient, and also understanding the data associated with that," says Galib.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings